Rafic Farah
University of Pittsburgh
32 Papers
11 Citations
Rafic Farah is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 20 publications.
Chat about Author
Papers
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
Michael Boyiadzis,Mounzer Agha,Robert L. Redner,Alison R. Sehgal,Annie Im,Jing-Zhou Hou,Rafic Farah,Kathleen A. Dorritie,Anastasios Raptis,Seah H. Lim,Hong Wang,Natalia Lapteva,Zhuyong Mei,Lisa H. Butterfield,Cliona M. Rooney,Theresa L. Whiteside +15 more
TL;DR: The trial demonstrated the safety and feasibility of adoptive cell therapy with "off-the-shelf" aNK cells in patients with refractory/relapsed AML and provides the foundation for future combination immunotherapy trials and for the optimization of aNK cell based therapies in Patients with AML.
152
The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States.
John A. Vargo,Arisha Patel,Scott M. Glaser,Goundappa K. Balasubramani,Rafic Farah,Stanley M. Marks,Sushil Beriwal +6 more
TL;DR: This study was aimed at defining patterns of care for NKTCL in the context of radiotherapy use and dose selection in the United States.
62
Leukapheresis in patients newly diagnosed with acute myeloid leukemia
Vipin Villgran,Mounzer Agha,Anastasios Raptis,Jing-Zhou Hou,Rafic Farah,Seah H. Lim,Robert L. Redner,Annie Im,Alison R. Sehgal,Kathleen A. Dorritie,Joseph E. Kiss,Daniel P. Normolle,Michael Boyiadzis +12 more
TL;DR: The high initial response rates in newly diagnosed AML patients fit to receive intensive chemotherapy suggest that leukapheresis could be beneficial in reducing the complications associated with hyperleukocytosis until systemic intensive chemotherapy commences.
23
Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
Christopher Melani,Rahul Lakhotia,Stefania Pittaluga,Milos D. Miljkovic,James D. Phelan,Jagan R. Muppidi,Craig J. Thomas,Michele Ceribelli,Frances A. Tosto,Craig A. Portell,Rafic Farah,Seung Tae Lee,Anna Marie Juanitez,Seth M. Steinberg,Elaine S. Jaffe,Mark Roschewski,Louis M. Staudt,Wyndham H. Wilson +17 more
TL;DR: It is hypothesized that combining agents that target unique survival pathways in a synergistic fashion will leverage efficacy and time-limited, cyclic dosing will limit toxicities.
18
IV pentamidine for primary PJP prophylaxis in adults undergoing allogeneic hematopoietic progenitor cell transplant.
Matthew J. Lim,Stebbings A,Sara J. Lim,Foor K,Jing-Zhou Hou,Rafic Farah,Anastasios Raptis,Stanley M. Marks,David Weber,Annie Im,Kathleen A. Dorritie,Alison R. Sehgal,Mounzer Agha,Seah H. Lim +13 more
TL;DR: IV pentamidine for primary PJP prophylaxis in adults undergoing allogeneic hematopoietic progenitor cell transplant and adult patients with prior PJP infection are referred for further studies.
14